Therapy-Related Satisfaction and Quality of Life for Japanese People with Diabetes Using Rapid-Acting Insulin Analogs: A Web-Based Survey.

IF 3.8 3区医学 Q2 Medicine

Diabetes Therapy Pub Date : 2024-07-01 Epub Date: 2024-05-18 DOI:10.1007/s13300-024-01584-9

Hitoshi Ishii, Yasutaka Maeda, Manaka Sato, Zhihong Cai, Makoto Imori

{"title":"Therapy-Related Satisfaction and Quality of Life for Japanese People with Diabetes Using Rapid-Acting Insulin Analogs: A Web-Based Survey.","authors":"Hitoshi Ishii, Yasutaka Maeda, Manaka Sato, Zhihong Cai, Makoto Imori","doi":"10.1007/s13300-024-01584-9","DOIUrl":null,"url":null,"abstract":"Introduction: People with diabetes require insulin to regulate blood glucose (BG); rapid-acting insulin analogs (RAIA) represent one approach for BG management. New fast-acting RAIA administered at the start of a meal suppress postprandial BG better than conventional RAIA. New RAIA are expected to confer higher treatment satisfaction and improved quality of life (QOL) than conventional RAIA.Methods: This cross-sectional, web-based survey in Japan (November 2022) included people with diabetes (type 1/2), aged ≥ 18 years, registered in the Rakuten Insight Diabetes Panel, using new and/or conventional RAIA. RAIA-specific satisfaction was evaluated by questions on RAIA use (scores: 1 [not at all satisfied]; 7 [very satisfied]) and QOL by the Diabetes Therapy-Related (DTR)-QOL questionnaire (scores: 0-100, 100 = best) for the whole population (primary endpoint) and for new versus conventional RAIA users (secondary endpoint). Multiple regression models were used to compare new versus conventional RAIA users.Results: The analysis population comprised 217 people with diabetes (new RAIA, n = 109; conventional RAIA, n = 108). Mean (standard deviation) RAIA-specific satisfaction scores ranged from 5.1 (1.2) to 5.4 (1.2); DTR-QOL total score was 51.6 (20.4). RAIA satisfaction scores were numerically higher for new versus conventional RAIA users; no difference in DTR-QOL total score was observed. DTR-QOL satisfaction with treatment domain score was significantly higher in new versus conventional RAIA users (least squares mean difference [standard error]: 7.3 [3.1]; 95% confidence interval: 1.2, 13.4; P = 0.0197). RAIA-specific satisfaction was higher among patients who discussed BG sufficiently with their doctor versus those who did not.Conclusions: New RAIA users have greater treatment satisfaction than conventional RAIA users. QOL was similar among new and conventional RAIA users, except for satisfaction with treatment, which was significantly higher among new RAIA users. Detailed explanations from the doctor to the person with diabetes about the relationship between new RAIA and BG status are essential. A graphical plain language summary is available with this article.","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":"1577-1595"},"PeriodicalIF":3.8000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11211310/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13300-024-01584-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: People with diabetes require insulin to regulate blood glucose (BG); rapid-acting insulin analogs (RAIA) represent one approach for BG management. New fast-acting RAIA administered at the start of a meal suppress postprandial BG better than conventional RAIA. New RAIA are expected to confer higher treatment satisfaction and improved quality of life (QOL) than conventional RAIA.

Methods: This cross-sectional, web-based survey in Japan (November 2022) included people with diabetes (type 1/2), aged ≥ 18 years, registered in the Rakuten Insight Diabetes Panel, using new and/or conventional RAIA. RAIA-specific satisfaction was evaluated by questions on RAIA use (scores: 1 [not at all satisfied]; 7 [very satisfied]) and QOL by the Diabetes Therapy-Related (DTR)-QOL questionnaire (scores: 0-100, 100 = best) for the whole population (primary endpoint) and for new versus conventional RAIA users (secondary endpoint). Multiple regression models were used to compare new versus conventional RAIA users.

Results: The analysis population comprised 217 people with diabetes (new RAIA, n = 109; conventional RAIA, n = 108). Mean (standard deviation) RAIA-specific satisfaction scores ranged from 5.1 (1.2) to 5.4 (1.2); DTR-QOL total score was 51.6 (20.4). RAIA satisfaction scores were numerically higher for new versus conventional RAIA users; no difference in DTR-QOL total score was observed. DTR-QOL satisfaction with treatment domain score was significantly higher in new versus conventional RAIA users (least squares mean difference [standard error]: 7.3 [3.1]; 95% confidence interval: 1.2, 13.4; P = 0.0197). RAIA-specific satisfaction was higher among patients who discussed BG sufficiently with their doctor versus those who did not.

Conclusions: New RAIA users have greater treatment satisfaction than conventional RAIA users. QOL was similar among new and conventional RAIA users, except for satisfaction with treatment, which was significantly higher among new RAIA users. Detailed explanations from the doctor to the person with diabetes about the relationship between new RAIA and BG status are essential. A graphical plain language summary is available with this article.

Abstract Image

查看原文本刊更多论文

使用速效胰岛素类似物的日本糖尿病患者与治疗相关的满意度和生活质量：基于网络的调查。

简介：糖尿病患者需要胰岛素来调节血糖；速效胰岛素类似物（RAIA）是血糖管理的一种方法。新型速效胰岛素类似物在餐前给药比传统速效胰岛素类似物更能抑制餐后血糖。与传统 RAIA 相比，新型 RAIA 可提高治疗满意度并改善生活质量（QOL）：这项在日本进行的横断面网络调查（2022 年 11 月）的对象包括年龄≥ 18 岁、在乐天 Insight 糖尿病小组注册、使用新型和/或传统 RAIA 的糖尿病患者（1/2 型）。通过RAIA使用问题（评分：1[完全不满意]；7[非常满意]）和糖尿病治疗相关（DTR）-QOL问卷（评分：0-100，100=最佳）对整个人群（主要终点）和新RAIA用户与传统RAIA用户（次要终点）的RAIA特定满意度进行评估。采用多元回归模型对 RAIA 新用户和传统用户进行比较：分析对象包括 217 名糖尿病患者（新 RAIA，n = 109；传统 RAIA，n = 108）。RAIA特定满意度的平均分（标准差）从5.1（1.2）到5.4（1.2）不等；DTR-QOL总分为51.6（20.4）。新RAIA用户与传统RAIA用户的RAIA满意度得分在数值上更高；DTR-QOL总分没有差异。新 RAIA 用户的 DTR-QOL 治疗满意度领域得分明显高于传统 RAIA 用户（最小二乘法均值差异 [标准误差]：7.3 [3.1]；95% 置信区间：1.2, 13.4；P = 0.0197）。与未与医生充分讨论生物碱的患者相比，RAIA特定患者的满意度更高：结论：与传统 RAIA 用户相比，新 RAIA 用户对治疗的满意度更高。新RAIA用户和传统RAIA用户的QOL相似，但新RAIA用户对治疗的满意度明显更高。医生必须向糖尿病患者详细解释新 RAIA 与血糖状况之间的关系。本文附有通俗易懂的图表摘要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes Therapy Medicine-Endocrinology, Diabetes and Metabolism

CiteScore

6.90

自引率

7.90%

发文量

130

审稿时长

6 weeks

期刊介绍： Diabetes Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all areas of diabetes. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Diabetes Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.